Viridian Therapeutics (VRDN) grants options and RSUs to Chief Legal Officer

Rhea-AI Filing Summary

Viridian Therapeutics’ Chief Legal Officer Jennifer Tousignant reported multiple equity compensation transactions. On March 2, 2026, she received a grant of stock options for 119,300 shares and 23,850 restricted stock units, each RSU representing one share of common stock. The option grant vests in 48 equal monthly installments after the grant date, while the RSUs vest over four years, with 25% vesting on each yearly anniversary of the grant date, subject to continued service.

On March 3, 2026, 5,169 RSUs vested and were converted into 5,169 shares of common stock. In connection with this vesting, 1,724 shares of common stock were disposed of at $29.32 per share to cover tax withholding obligations. After these transactions, she directly held 15,510 RSUs and 3,445 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tousignant Jennifer

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		5,169	A	(2)	5,169	D
Common Stock	03/03/2026		F		1,724	D	$29.32	3,445	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.25	03/02/2026		A		119,300		(1)	03/02/2036	Common Stock	119,300	$0.00	119,300	D
Restricted Stock Units	(2)	03/02/2026		A		23,850		(3)	(3)	Common Stock	23,850	$0.00	23,850	D
Restricted Stock Units	(2)	03/03/2026		M			5,169	(4)	(4)	Common Stock	5,169	$0.00	15,510	D

Explanation of Responses:

1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

4. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

	Jennifer Tousignant	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Viridian Therapeutics (VRDN) grant to its Chief Legal Officer?

Viridian granted its Chief Legal Officer stock options for 119,300 shares and 23,850 restricted stock units. The options vest in 48 equal monthly installments, while the RSUs vest over four years in 25% annual increments, all conditioned on continued service.

How do the new restricted stock units for Viridian (VRDN) vest over time?

The RSUs vest over four years, with 25% of the units vesting on each yearly anniversary of the March 2, 2026 grant date. Vesting is subject to the executive’s continued service to Viridian Therapeutics through each vesting date, aligning compensation with long-term retention.

What happened when Viridian (VRDN) RSUs vested for the Chief Legal Officer?

On March 3, 2026, 5,169 RSUs vested and converted into 5,169 shares of Viridian common stock. To satisfy tax withholding obligations, 1,724 of those shares were disposed of at $29.32 per share, leaving a smaller net share position outstanding afterward.

How many Viridian (VRDN) shares and RSUs does the Chief Legal Officer hold after these transactions?

Following the reported transactions, the Chief Legal Officer directly held 3,445 shares of Viridian common stock and 15,510 restricted stock units. These positions reflect the recent RSU vesting, related tax-withholding share disposition, and the remaining unvested equity awards reported in the Form 4 filing.

Is the Form 4 for Viridian (VRDN) a market purchase or sale by the Chief Legal Officer?

The Form 4 primarily reflects equity grants and RSU vesting, not an open-market trade. The only share disposition involves 1,724 shares withheld at $29.32 per share to cover tax liabilities, a common non-discretionary mechanism in stock-based compensation.